The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Prestige Consumer Healthcare Inc.
PBH · the NYSE · USD · Market cap $2.5B · 890 employees
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
Screened 2026-08-26 · the tape above runs as of 16:37 UTC · 29 Aug · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Prestige Consumer Healthcare Inc. holds its Distribution at $52.15. The statistical read favours the buyers, held for 9 days.
As held on the ledger · 2026-08-26
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 9 days
Price at the screen
$52.15
Valuation
14.61 trailing · 10.26 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.33
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.92%
Below 33%
Interest-bearing debt is just 29.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
7.80%
Below 49%
Money owed to the company is 7.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 43.8% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +34% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Everyday Remedies Trade Below Their Steady Value
Picture a bathroom cabinet full of familiar painkillers and cough treatments that sell year after year regardless of economic noise. Prestige Consumer Healthcare makes exactly those over-the-counter staples across North America and abroad, yet its revenue has slipped 5 percent while the shares sit at just 9.8 times forward earnings with a 17 percent profit margin and a clean ethical screen.
The valuation gap to our $75 fair value looks attractive on paper, and the 10 percent return on equity plus analyst median target of $70 hint at some support. Still, the opportunity rating stays at none because the business shows no clear growth driver or durable edge to close that gap quickly.
Revenue contraction and an unknown competitive position keep the setup fragile even at this price. Currency moves or retailer shifts could easily erode the apparent margin of safety further. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PBH trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-08Markup · changed$54.85+14.7%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-07-18Distribution$47.82+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-07-03Distribution$47.82+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$47.82Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
